Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.

Abstract

Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or… (More)
DOI: 10.1111/bjh.13262

2 Figures and Tables

Topics

  • Presentations referencing similar topics